Published in Clin Trials on January 01, 2005
Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations. J Diabetes Sci Technol (2012) 1.37
Acute anti-inflammatory approaches to ischemic stroke. Ann N Y Acad Sci (2010) 1.05
Advancing clinical trial design in pulmonary hypertension. Pulm Circ (2013) 0.84
Clinical Trials of Immunomodulation in Ischemic Stroke. Neurotherapeutics (2016) 0.84
A change is in the wind as 'adaptive' clinical trials catch on. Nat Med (2009) 0.77
Randomized clinical trials in stroke research. J Investig Med (2010) 0.76
Decision-theoretic designs for small trials and pilot studies: A review. Stat Methods Med Res (2015) 0.75
Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment. Stat Med (2016) 0.75
Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity. BMC Med Res Methodol (2017) 0.75
Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat (2007) 4.78
Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group. J Biopharm Stat (2006) 4.41
An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol (2008) 3.90
Where the BOLD signal goes when alpha EEG leaves. Neuroimage (2006) 1.86
Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci (2012) 1.80
Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab (2007) 1.26
Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov (2012) 1.18
Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clin Trials (2010) 1.17
Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke. Stroke (2003) 1.11
A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug. Clin Trials (2010) 1.10
Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov Disord (2008) 1.08
Robotic measurement of arm movements after stroke establishes biomarkers of motor recovery. Stroke (2013) 1.05
Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group. J Biopharm Stat (2010) 0.95
Charting a path toward combination therapy for Alzheimer's disease. Expert Rev Neurother (2014) 0.87
Role of mechanistically-based pharmacokinetic/pharmacodynamic models in drug development : a case study of a therapeutic protein. Clin Pharmacokinet (2006) 0.86
Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder. J Pharmacokinet Pharmacodyn (2009) 0.82
Building a roadmap for developing combination therapies for Alzheimer's disease. Expert Rev Neurother (2015) 0.80
Phase I trials: from traditional to newer approaches part II. J Psychiatr Pract (2011) 0.80
UK-279,276, a neutrophil inhibitory glycoprotein, in acute stroke: tolerability and pharmacokinetics. Stroke (2003) 0.79
Phase I trials: from traditional to newer approaches. Part I. J Psychiatr Pract (2011) 0.78
Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition. Pharm Res (2005) 0.78
A longitudinal model for non-monotonic clinical assessment scale data. J Pharmacokinet Pharmacodyn (2005) 0.78
A bayesian dose-finding design adapting to efficacy and tolerability response. J Biopharm Stat (2012) 0.76
Assessing combination treatments in acute stroke: preclinical experiences. Behav Brain Res (2005) 0.76
How Adaptive Trial Designs can Increase Efficiency in Psychiatric Drug Development: A Case Study. Innov Clin Neurosci (2011) 0.75